Doxorubicin Hydrochloride Injection, Solution
Product Images NDC 0069-0255

This text provides information on clinical trials regarding Doxorubicin-based treatments. It includes the hazard ratios and 95% confidence intervals for several studies, such as NSABP B-15, SECSG 2, ONCOFRANCE, SE Sweden BCG A, NSABC Israel Br0283, and Austrian BCSG 3. The graph shows the comparison of Doxorubicin-based treatment with CMF and the boundary of non-inferiority with CMF.*

The text describes a table which displays the hazard ratio and trial with their 95% CI for different studies such as NSABP B-15, SECSG 2c, ONCOFRANCE, SE Sweden BCG A, NSABC Israel Br0283, and Austrian BCSG 3. The table is related to "Doxo based" studies which are compared to CMF (an abbreviation for a type of chemotherapy). The table displays whether Doxo is better or worse than CMF.*

This is a description of a medication that comes in a single-dose Cytosafe® Vial, with an NDC number of 0069-4004-05. It is a sterile, isotonic solution for intravenous use only and contains 10mg/5mL of hydrochloride injection. The medication should be stored refrigerated between 2° and 8°C (36° and 46°F) and should be protected from light. Cytotoxic Agent caution is stated on the label, and it is recommended to discard any unused portion of the medication. The accompanying prescribing information should be referred to for dosage and usage instructions. The medication is manufactured in Australia and distributed by Pfizer Labs, a division of Pfizer Inc.*

This text describes the storage, dosage, and use information for a medication called "Stelle, sotonic Solution" which contains 2 mg of doxorubicin hydrochloride and 9mg of sodium chloride per milliliter. The solution's pH is adjusted to 3.0 with hydrochloric acid. It is recommended to store the medication between 36° and 46°F and protect from light. The prescribing information should be consulted before use. The text also includes information about the manufacturer and packaging of the medication.*

This is a prescription-only single-dose medication with the National Drug Code (NDC) 0069-4015-10. The medication contains 20mg/10mL of DOXOrubicin Hydrochloride Injection in a sterile, isotonic solution. It is used intravenously and should be stored refrigerated between 2°C and 8°C (36°F and 46°F) and protected from light. Unused portions should be discarded. This medication is a cytotoxic agent and should be used with caution. Dosage and use information are available in the accompanying prescribing information. The manufacturer of this medication is not available, but it was made in Australia. The product is distributed by Pfizer Labs, and the lot and expiration information are included.*

This is a description of a medication called DOXOrubicin Hydrochloride Injection, a cytotoxic agent used for intravenous use only. The solution is stored refrigerated between 2 -1 (36° and 46°F), and it's recommended to protect from light. The dosage and use instructions are not available in this text. The solution comes in a single-dose Cytosafe Vial, and the unused portion must be discarded. Each milliliter contains 2g of doxorubicin hydrochloride and 9mg of sodium chloride. This medication is manufactured in Australia.*

This is a description of a medication with the NDC code 0069-4026-25, which is a single-dose prescription medication that should be discarded if any leftovers. The medication contains DOXOrubicin Hydrochloride Injection at a concentration of 2 mg/mL, and is intended to be used intravenously. This medication is classified as a cytotoxic agent, requires refrigeration at 20 and 8° (36°-46°F) and must be protected from light. The dosages and usage instructions are provided in the accompanying prescribing information. It is manufactured in Australia and uses the Cytosafe® Vial for packaging.*

This is a description for a medication called "DOXOrubicin Hydrochloride Injection." Each milliliter contains 2 mg of Doxorubicin Hydrochloride and 1 mg of Sodium Chloride. The solution is stored refrigerated between 36° and 46°F, and it is important to protect it from light. The dosage and use information can be found in the accompanying prescribing information. The solution should be discarded if unused after single-dose use.*

This is a description of a medication called DOXOrubicin Hydrochloride Injection, which is a cytotoxic agent used for intravenous use only. It is supplied in a multiple-dose vial containing 200mg/100ml of the solution. It is stored under refrigeration and is packaged in a sterile, isotonic solution within a special vial called Cytosafe® Vial that is designed to ensure maximum safety. The solution contains 2mg of doxorubicin hydrochloride and 9mg of sodium chioride per milliliter, and must be prescribed by a physician. The pH of the solution is adjusted to 3.0 with hydrochloric acid, USP. This medication is manufactured in Australia and distributed by Pfizer Labs.*

Description: This is a medical product description for DOXOrubicin Hydrochloride, a sterile isotonic solution made in Australia. It is a cytotoxic agent with a dosage of 200mg/100mL for intravenous use only. The storage requirement is between 2°C and 46°C. It comes in a multiple-dose vial and caution is advised while handling.*